Abstract
At first sight the description of the palliative hormonal treatment methods in disseminated malignant endometrial tumors is a simple exercise requiring only a few minutes. This anticipation is true if only the presently established therapeutic models are described.
The own investigations were supported by the »Deutsche Forschungsgemeinschaft« (Schu 631/1-1)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kaiser R: Die Wirkung von Gestagenen beim Korpuskarzinom. Arch. Gynaek. 193: 195, 1959
Kelley RM, Baker WH: Progestational agents in the treatment of carcinoma of the endometrium. New Engl. J. Med. 264: 216, 1961
Richardson GS, Mac Laughlin DT: Hormonal biology of endometrial cancer. UICC Technical Report Series 42, 1978
Brooks SC, Christensen C, Meyers S, Corombos J, Pack BA: Endocrine implications of endometrial estrogen sulfurylation. In: “Steroids and endometrial cancer”. Jasonni VM, Nenci J, Flamigni C (eds). Raven Press, New York, p. 145, 1983
Pannuti F, Giovannini M, Martoni A, Fruet F, Rubino J, Vecchi F, Zanichelli L, Pieromaldi S: Effects of high dose oral medroxyprogesterone acetate (MPA) on plasma levels of T3, T4, TSH, LH, FSH, PRL, 17ß- oestradiol, testosterone and aldosterone. IRCS Med. Sei, 8: 764, 1980
Pannuti F, Martoni A, Camaggi CM et al: High dose medroxyprogesterone acetate in oncology: history, clinical use and pharmacokinetics. In: “Int. Symp. Medroxy progesterone Acetate”. Cavalli F et al (eds), Excerpta Medica, p. 5, 1982
Schulz KD, Schmidt-Rhode P, Sturm G: High dose medroxyprogesterone acetate in breast cancer-present state of knowledge. In: “Progress in hormono- and chemotherapy”. Robustelli della Cuna G, Nagel GA, Lanius, P (eds) Kehrer, Freiburg, p. 21, 1985
Schulz KD, Schmidt-Rhode P, Zippel HH, Sturm G: New Concepts of Adjuvant Drug Treatment in Endometrial Cancer. In: “Endometrial Cancer”. Schulz KD, King RJB, Pollow K, Taylor RW (eds), Zuckschwerdt, München, p. 169, 1987
Swenerton KD: Antioestrogens for the treatment of endometrial cancer. In: “Endometrial Cancer”. Schulz K-D, King RJB, Pollow K, Taylor RW (eds), Zuckschwerdt, München, p. 165, 1987
Jordan VC: Resistance to antioestrogen therapy: a challenge for the future. In: Cavalli F (Ed): Endocrine therapy of breast cancer III. Springer Berlin, p.51–60, 1989
Schulz KD, Sturm G, Schmidt-Rhode P, Hackenberg R, Künzig HJ: Pharmakokinetik und Pharmakodynamik der Antiöstrogene. In: Kubli F et al (Eds): Neue Wege in der Brustkrebsbehandlung. Zuckschwerdt München, p. 62, 1983
Murray RML, Pitt P: Treatment of advanced metastatic breast cancer, carcinoma of the prostate and endometrial cancer with aminoglutethimide. In: “Aminoglutethimide as an aromatase inhibitor in the treatment of cancer”. Nagel GA, Santen RJ (eds) Hans Huber Publishers Bern, p. 109, 1984
Santen RJ, Lipton A, Harvey H, Boucher AE, Henderson C: Pharmacological mechanisms of oestrogen Suppression with aminoglutethimide in women with breast cancer. In: “Aminoglutethimide as an aromatase inhibitor in the treatment of cancer”. Nagel GA, Santen RJ (eds), Hans Huber Publishers Bern, p. 38, 1984
Schulz KD, Rück A, Zippel HH, Hofmann J, Hackenberg R, Schmidt-Rhode P, Hölzel F, Pfisterer Y: Endometrial Cancer, Advances in Clinical Oncology 3: 95, 1988
Bonte J, Decoster MJ, Ide P, Billiet G: Hormonoprophylaxis and Hormonotherapy in the treatment of Endometrial Adenocarcinoma by means of Medroxyprogesterone Acetate. Gynecol. Oncol. 6: 60, 1978
Bonte J. Hormone dependency and hormone responsiveness of endometrial adenocarcinoma to estrogens, progestogens and antiestrogens. In: “Role of medroxyprogesterone in endocrine- related tumours”. Campio L, Robustelli della Cuna G, Taylor RW (eds) Raven Press, New York, p. 141, 1983
Robustelli della Cuna G: Comprehensive guide to the therapeutic use of medroxy progesterone acetate in oncology. Farmitalia Press, Milano 1987
Hackenberg R, Hofmann J, Wolff G, Hölzel F, Schulz KD: Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary carcinoma cell growth. J Cancer Res Clin Oncol (in press) 1990
Hofmann J, Kunzmann R, Drescher A, Hackenberg R, Hölzel F, Schulz KD: Growth regulation of human endometrial carcinoma cells in vitro by steroid hormones and growth factors. Proc Internat Congr Hormones and Cancer, Raven Press, New York, p. 452, 1988
Rendina GM: High dose medroxyprogesterone acetate in the therapy of endometrial carcinoma. In: “Medroxyprogesterone acetate (MPA) in the therapy of hormone-dependent tumours”. Nagel GA, Robustelli della Cuna G, Lanius P (eds), Kehrer Freiburg, p. 161, 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schulz, KD., Hofmann, J., Hackenberg, R., Emons, G., Schmidt-Rhode, P., Sturm, G. (1991). Palliative Hormonal Treatment in Endometrial Carcinoma. In: Kleine, W., Meerpohl, HG., Pfleiderer, A., Profous, C.Z. (eds) Therapie des Endometriumkarzinoms. AGO Arbeitsgemeinschaft für Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76950-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-76950-4_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-54571-2
Online ISBN: 978-3-642-76950-4
eBook Packages: Springer Book Archive